UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

被引：0

作者：

E Martinez-Balibrea

A Abad

A Martínez-Cardús

A Ginés

M Valladares

M Navarro

E Aranda

E Marcuello

M Benavides

B Massutí

A Carrato

L Layos

J L Manzano

V Moreno

机构：

[1] Medical Oncology Service,Department of Clinical Sciences

[2] Institut Català d'Oncologia,undefined

[3] Hospital Germans Trias I Pujol. C/Ctra. Canyet s/n,undefined

[4] Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (FIGTP). C/Ctra. De Can Ruti,undefined

[5] camí de les escoles s/n,undefined

[6] Medical Oncology Service,undefined

[7] Complejo Hospitalario Universitario Juan Canalejo,undefined

[8] C/Lugar Xubias De Arriba 84,undefined

[9] A Coruña 15006,undefined

[10] Spain,undefined

[11] Medical Oncology Service,undefined

[12] Institut Català d'Oncologia,undefined

[13] Hospital Duran I Reynals,undefined

[14] Avda. Gran Vía s/n Km 2.7,undefined

[15] L'Hospitalet de Llobregat 08907,undefined

[16] Spain,undefined

[17] Medical Oncology Service,undefined

[18] Hospital Universitario Reina Sofía,undefined

[19] C/Menéndez Pidal s/n,undefined

[20] Córdoba 14004,undefined

[21] Spain,undefined

[22] Medical Oncology Service,undefined

[23] Hospital de la Santa Creu I Sant Pau,undefined

[24] C/Sant Antoni Maria Claret,undefined

[25] 167,undefined

[26] Barcelona 08025,undefined

[27] Spain,undefined

[28] Medical Oncology Service,undefined

[29] Hospital Carlos Haya,undefined

[30] Avda. Carlos Haya s/n,undefined

[31] Medical Oncology Service,undefined

[32] Hospital General Universitario de Alicante,undefined

[33] Avda. Pintor Baeza s/n,undefined

[34] Medical Oncology Service,undefined

[35] Hospital General Universitario de Elche,undefined

[36] Camí Almassera 11,undefined

[37] Elche 03203,undefined

[38] Spain,undefined

[39] Biostatistics and Bioinformatics Unit,undefined

[40] Institut Català d'Oncologia,undefined

[41] Hospital Duran i Reynals,undefined

[42] Avda. Gran Vía s/n Km 2.7,undefined

[43] Institut d'Investigació de Bellvitge,undefined

[44] Feixa Llarga s/n,undefined

[45] University of Barcelona,undefined

[46] Feixa Llarga s/n,undefined

[47] L'Hospitalet de Llobregat 08907,undefined

[48] Spain,undefined

[49] Current address: Cancer Control and Prevention Service,undefined

[50] Institut Català d'Oncologia,undefined

来源：

British Journal of Cancer | 2010年 / 103卷

关键词：

colorectal; 5FU; irinotecan; toxicity; polymorphisms;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：581 / 589

页数：8

共 50 条

[1] UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
Martinez-Balibrea, E.
Abad, A.
Martinez-Cardus, A.
Gines, A.
Valladares, M.
Navarro, M.
Aranda, E.
Marcuello, E.
Benavides, M.
Massuti, B.
Carrato, A.
Layos, L.
Manzano, J. L.
Moreno, V.
BRITISH JOURNAL OF CANCER, 2010, 103 (04) : 581 - 589
[2] Pharmacogenetic analysis of TS and UGT1A polymorphisms predictive for response and toxicity in Spanish patients with advanced colorectal cancer treated with first-line irinotecan and 5-fluorouracil
Martinez-Balibrea, E.
Abad, A.
Valladares, M.
Martinez-Villacampa, M.
Aranda, E.
Marcuello, E.
Benavides, M.
Martinez-Cardus, A.
Gines, A.
Manzano, J. L.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[3] UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan
Carlini, LE
Meropol, NJ
Bever, J
Andria, ML
Hill, T
Gold, P
Rogatko, A
Wang, H
Blanchard, RL
CLINICAL CANCER RESEARCH, 2005, 11 (03) : 1226 - 1236
[4] Combination with irinotecan - the reference first-line therapy for advanced colorectal cancer
Wilke, HW
ONKOLOGIE, 2000, 23 : 32 - 34
[5] Refining the UGT1A Haplotype Associated with Irinotecan-Induced Hematological Toxicity in Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Irinotecan-Based Regimens
Levesque, Eric
Belanger, Anne-Sophie
Harvey, Mario
Couture, Felix
Jonker, Derek
Innocenti, Federico
Cecchin, Erica
Toffoli, Giuseppe
Guillemette, Chantal
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 345 (01): : 95 - 101
[6] The comprehensive analysis of UGT1A genetic polymorphisms in patients with metastatic gastrointestinal cancer treated with irinotecan chemotherapy
Tsujinaka, T.
Satoh, T.
Ura, T.
Sasaki, Y.
Yamazaki, K.
Munakata, M.
Yamada, Y.
Ishizuka, N.
Hyodo, I.
Sakata, Y.
EJC SUPPLEMENTS, 2009, 7 (02): : 144 - 144
[7] Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
Cecchin, Erika
Innocenti, Federico
D'Andrea, Mario
Corona, Giuseppe
De Mattia, Elena
Biason, Paola
Buonadonna, Angela
Toffoli, Giuseppe
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : 2457 - 2465
[8] UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy
Qianqian Yu
Tao Zhang
Conghua Xie
Hong Qiu
Bo Liu
Liu Huang
Ping Peng
Jueping Feng
Jigui Chen
Aihua Zang
Xianglin Yuan
Cancer Chemotherapy and Pharmacology, 2018, 82 : 87 - 98
[9] UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy
Yu, Qianqian
Zhang, Tao
Xie, Conghua
Qiu, Hong
Liu, Bo
Huang, Liu
Peng, Ping
Feng, Jueping
Chen, Jigui
Zang, Aihua
Yuan, Xianglin
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 87 - 98
[10] Polymorphisms in UGT1A1 and UGT1A7 may predict irinotecan toxicity in patients with advanced colorectal cancer
Lastraioli, S.
Ponzanelli, A.
Leonardi, F.
Marroni, P.
Serra, M.
Sonaglio, C.
Loiacono, F.
Zuccaro, D.
Naldi, N.
Franzini, E.
Boni, L.
Paganuzzi, M.
Ardizzoni, A.
Chiara, S.
Notaro, R.
ANNALS OF ONCOLOGY, 2006, 17 : XI47 - XI47

← 1 2 3 4 5 →